ClinicalTrials.gg
RecruitingNCT07175441Updated Apr 24, 2026

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

A Phase 2 interventional study of RBS2418 and STRIDE (durvalumab + tremelimumab) in Advanced Unresectable Hepatocellular Carcinoma, sponsored by Riboscience, LLC.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Riboscience, LLC. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
104th of 775
220 · median 36
Started
2026
with 35 others
Phase 2
259 of 926
40 open now
Primary completion
2027-04
later than 103 of 244 live
Registered
892nd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 104th largest by planned enrollment of the 775 interventional ones that give a count, is one of 36 that started in 2026, is one of 259 in phase 2, reaches primary completion later than 103 of the 244 other live ones, and was the 892nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.

Read the detailed description

In this Phase 2a study, participants must have advanced, unresectable HCC confirmed by radiology, histology or cytology. Participants must be eligible to receive the STRIDE regimen as first line therapy. Participants must have measurable disease per RECIST 1.1, an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2, and predicted life expectancy of at least 12 weeks.

Up to approximately 220 participants will be enrolled and will receive therapy as part of their respective treatment group. Participants will receive study treatment of RBS2418 at two different dose levels (200mg and 800mg) twice daily in combination with STRIDE or STRIDE alone with a treatment period consisting of 28-day cycles up to two years or until there is progressive disease, death, withdrawal, or study completion, whichever comes first.

Adverse Events (AEs) will be monitored throughout the study and graded in severity according to the guidelines outlined in the NCI CTCAE v5.0. AEs will be collected until up to 30 days after the last dose of RBS2418 or until resolution, whichever comes first. SAEs will be collected for 90 days after the last dose of RBS2418, or if the participant initiates new anti-cancer therapy, then 30 days after the RBS2418 last dose, whichever is earlier.

03

Conditions studied

  • Advanced Unresectable Hepatocellular Carcinoma

Keywords

  • Advanced Unresectable Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age on the day of signing .
  2. Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as therapy.
  3. Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available).

Exclusion criteria

Exclusion Criteria:

  1. BCLC stage D disease at the time of screening or prior to first dose of RBS2418.
  2. class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment.
  3. Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation).
  4. Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Active comparator
    Arm A: RBS2418, 200mg BID, plus STRIDE

    RBS2418 200 mg PO, BID in combination with STRIDE regimen

    Drug: RBS2418 · Drug: STRIDE (durvalumab + tremelimumab)

  • Active comparator
    Arm B: RBS2418, 800mg BID, plus STRIDE

    RBS2418 800 mg PO, BID in combination with STRIDE regimen

    Drug: RBS2418 · Drug: STRIDE (durvalumab + tremelimumab)

  • Active comparator
    Arm C: STRIDE alone (control)

    STRIDE regimen

    Drug: STRIDE (durvalumab + tremelimumab)

Interventions

  • RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.

  • DrugSTRIDE (durvalumab + tremelimumab)

    STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks

This study also gives Durvalumab, Tremelimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time in months from randomization until the first radiographic documentation of objective progression, as assessed using RECIST 1.1, or death from any cause.

    Time frame: From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.

Secondary outcomes

  1. Overall Survival (OS)

    Time in months from the date of randomization to the date of death from any cause.

    Time frame: From randomization until death from any cause, assessed up to 2 years.

  2. Overall Response Rate (ORR) by RECIST 1.1

    ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) during the study using RECIST 1.1, among those with measurable disease.

    Time frame: From randomization to initial response, assessed up to 2 years

  3. Duration of Response (DOR) by RECIST 1.1

    DOR is defined as time from initial response to disease progression or death.

    Time frame: From initial response to disease progression or death, assessed up to 2 years

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve a complete response (CR), partial response (PR) or stable disease (SD).

    Time frame: From randomization to end of treatment or disease progression, assessed up to 2 years.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartActual
Apr 10, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Aug 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07175441
Lead sponsor
Riboscience, LLC.
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Apr 10, 2026
Primary completion
Apr 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Riboscience Clinical Trials
Contact
clinicaltrials@riboscience.com
415-754-3182

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENPP1 Inhibitor RBS2418

Start the discussion